hotspot -WSS

hotspot

author：knowledge 2025-09-29 22:52:45 - browse：28968

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT.

Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law, the Food and Drug Administration’s move could give doctors an avenue to prescribe the medications to some Medicare patients.

Wegovy’s new label indicates that the drug can be used to reduce the risk of major heart complications for people who are overweight or obese and have existing heart disease, Novo said in a statement Friday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： CDC recommends RSV monoclonal antibody for infants

entertainment

WSS

ARCH Venture Partners is raising $3 billion for a life sciences fund

The cancer stories no one wants to hear

The real point of Kenneth Smith’s execution by nitrogen gas

The a glaring gap in research on serious mental illness and primary care

FDA scientists endorse Pfizer/BioNTech Covid

Juul spent big to court Black leaders to promote its e

knowledge

hotspot

hotspot

How one medical school became remarkably diverse

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Malaria cases in Florida and Texas: Here’s what you need to know

Novo Nordisk to expand supply of Wegovy for U.S. patients

Novavax promises a turnaround & Lilly roils the obesity market

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Tori Bowie and the unacceptable rates of Black maternal death

Apple Vision Pro: A first look at health apps on the new VR headset

Medicare details structure of new drug price negotiation program

The a glaring gap in research on serious mental illness and primary care

explore

The a glaring gap in research on serious mental illness and primary care

A $475,000 price tag for a new cancer drug: crazy or meh?

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

FDA scientists endorse Pfizer/BioNTech Covid

When waiting feels immoral: Empathy in the emergency department

Alnylam reports growth in sales of rare disease treatments

entertainment

Wikipedia

leisure time

focus